ClinicalTrials.gg
RecruitingNCT02486562iCMSUpdated Oct 27, 2026

iConquerMS™ - A Patient-Powered Research Network for Multiple Sclerosis

An observational study in Multiple Sclerosis, sponsored by Accelerated Cure Project for Multiple Sclerosis. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Accelerated Cure Project for Multiple Sclerosis · Observational

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
20,000
Sex
All
01

Study summary

iConquerMS™ is a research initiative developed by and for people with multiple sclerosis (MS) to contribute their health data and ideas to advance and accelerate research into MS. iConquerMS welcomes adults with MS and others interested in advancing MS research, children and teens with MS and their family members (via iConquerMS Kids \& Teens) and MS caregivers (via iConquerMS Caregivers) to participate.

Read the detailed description

The purpose of this study is to create a Multiple Sclerosis Patient-Powered Research Network (MS-PPRN) that includes at least 20,000 people with multiple sclerosis (MS) who contribute data on their health and other topics. Survey data will be made available to research scientists who are studying MS and similar diseases. Our goal is to use this data to answer questions that researchers and people with MS have regarding the disease, including its causes, treatments, and other topics.

While the MS-PPRN is focused on enrolling people with MS, people without MS are also welcome to participate in this research study. Adults are invited to participate via iConquerMS, while children and teens are invited to participate via iConquerMS Kids \& Teens. Adults who are MS caregivers may participate via the dedicated iConquerMS Caregivers site.

This study will be conducted online via the iConquerMS.org website. This is an ongoing study and will last for an indefinite period of time.

02

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Multiple Sclerosis
  • MS
03

In context

Multiple Sclerosis

3,264 studies on the registry are indexed under Multiple Sclerosis; 659 are open to participants now.

This study's planned enrollment of 20,000 is above the median of 100 across 970 observational studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

Accelerated Cure Project for Multiple Sclerosis is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Primary cohort is people with multiple sclerosis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 21 years of age or older at the time of or under 21 with parental consent and participant assent.

Exclusion criteria

Exclusion Criteria:

  • Unwilling or unable to provide .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
20,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • People diagnosed with Multiple Sclerosis
06

What researchers measure

Primary outcomes

  1. Number of people with multiple sclerosis who experience health-related quality-of-life changes

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Accelerated Cure Project
    Waltham, Massachusetts 02451, United States
    Recruiting
08

Updates

1 registry update since Sep 25, 2026
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date, oversight details and index terms
1 update, last Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Minor edits only
    + 4 other changes: identifiers, verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT02486562
Lead sponsor
Accelerated Cure Project for Multiple Sclerosis
Collaborators
Patient-Centered Outcomes Research Institute, Ogilvy, Arizona State University
Responsible party
Sponsor
First posted
Jul 1, 2015
Start date
Nov 2014
Primary completion
Oct 2030 (estimated)
Completion
Oct 2036 (estimated)
Last update
Oct 27, 2026

Study contacts

Sara Loud, MSEE, MBA
Contact
sloud@acceleratedcure.org
781-487-0032

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion